Background {#Sec1}
==========

Introduction {#Sec2}
------------

The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society \[[@CR1]\]. Worldwide, the number of oldest-old subjects is expected to increase to 71.2 million in 2050, a 5-fold increase of the current oldest-old population \[[@CR2], [@CR3]\]. The oldest-old have a high risk of developing dementia with a prevalence up to 40% \[[@CR4]\]. The increasing number of oldest-old subjects with dementia will have major clinical and financial consequences for patients, their families and society as a whole \[[@CR5]\].

Still a considerable number of subjects remain cognitively normal at high age, indicating the presence of protective factors for cognitive impairment in these subjects. Identification of these protective factors is crucial and will have implications for preventive strategies. In addition, identifying the neurodegenerative markers associated with cognitive impairment in the oldest-old, will enhance our understanding of the underlying pathophysiology in this specific age group.

The EMIF-AD 90+ study was set-up to investigate protective factors for cognitive impairment in the oldest-old. We will first provide an overview of the current status of research on this topic and then present the study outline of the EMIF-AD 90+ study.

Review on studies on cognitive impairment in the oldest-old {#Sec3}
-----------------------------------------------------------

We searched for studies focusing on protective factors for cognitive impairment in nonagenarians, which gave us two results: ***The 90+ Study*** in the USA and the Danish Birth Cohort Studies \[[@CR6], [@CR7]\]. Broadening the search to studies that started inclusion from the age of 85 years or focused on successful aging resulted in eight more studies: the H85 Gothenburg study, Leiden 85-plus Study, Newcastle 85+ Study, NonaSantfeliu study, Octabaix study, Project of Longevity and Aging in Dujangyan (PLAD), Umeå study and Vantaa 85+ Study \[[@CR8]--[@CR15]\]. Table [1](#Tab1){ref-type="table"} shows the design characteristics of these ten studies.Table 1Design characteristics of other 85+ and 90+ studies that include data about cognitive functioningDomainDanish Birth Cohort Studies \[6\]^a^H85 Gothen-burg study \[[@CR12]\]Leiden 85-plus Study \[[@CR9]\]Newcastle 85+ Study \[[@CR10]\]NonaSant-feliu study \[[@CR8]\]Octabaix study \[[@CR13]\]PLAD \[[@CR15]\]The 90+ Study, USA \[[@CR7]\]Umeå 85+ study \[[@CR14]\]Vantaa 85+ Study \[[@CR11]\]Cognitive reserve++++++++++Vascular comorbidity++++++++++Mood and sleep++++----++++Sensory system----++++--++--Physical performance and capacity+--++--++++--Genetics++++----++--+Hallmarks of aging^b^----+----+--+----Markers of neurodegeneration--+----------+----*PLAD* Project of Longevity and Aging in Dujangyan^a^Including the cohorts recruited in 1895, 1905, 1910 and 1915, data availability varies per cohort. ^b^Inflammation and senescence markers (for example p16, p53 and telomere associated foci)

### Protective factors for cognitive impairment in the oldest-old {#Sec4}

Table [2](#Tab2){ref-type="table"} summarizes the findings on the protective factors for cognitive impairment or dementia of the ten studies. A high level of education was found to be protective against dementia in the oldest-old and one study indicated that high cognitive activity, examined by looking at the time spend on reading, around age 90 years was related to resilience to dementia \[[@CR4], [@CR16]--[@CR18]\]. The influence of vascular comorbidities on cognition has been studied quite extensively in this age group. Most studies did not find an association between cholesterol levels and cognition in the oldest-old \[[@CR15], [@CR17], [@CR19]--[@CR22]\]. Hypertension has mostly been found to be protective in the oldest-old, especially when hypertension is diagnosed after the age of 80 years \[[@CR17], [@CR19], [@CR23]--[@CR27]\]. This is in contrast to studies that have shown a higher dementia risk in the presence of midlife hypertension \[[@CR28]\]. In addition, although midlife diabetes mellitus has been related to dementia in younger subjects \[[@CR29]\], the influence of diabetes mellitus on cognition might be less evident in the oldest-old \[[@CR11], [@CR30], [@CR31]\]. The protective effect related to the absence of stroke seemed to persist in the oldest-old \[[@CR18], [@CR32]\] and one study on atrial fibrillation and dementia did not find an association \[[@CR32]\]. The absence of depressive symptoms seemed to be associated with resilience to cognitive impairment, which is consistent with findings in younger subjects \[[@CR14], [@CR33], [@CR34]\]. One study related sleep quality to cognition and reported a higher sleep quality in subjects without cognitive impairment, which is in line with results in younger subjects \[[@CR35], [@CR36]\]. With regard to the sensory system, visual and auditory impairments have been associated with worse cognitive functioning in the oldest-old \[[@CR37], [@CR38]\] and although olfactory impairment has been associated with incident dementia in a younger age group \[[@CR39]\], no studies were found studying this in the oldest-old.Table 2Potential protective factors for cognitive impairment in the oldest-oldDomainPotential protective factorStudyAge^a^Sample size (N)Outcome variableResultCognitive reserveHigh level of educationH85 Gothenburg study \[[@CR18]\]85.7 (±0.05)No dementia: 794\
Dementia: 271DementiaProtectiveThe 90+ Study \[[@CR4]\]94 (90--106)No dementia: 536\
Dementia: 375DementiaProtectiveVantaa 85+ Study \[[@CR17]\]88.4 (85.0--104.0)No incident dementia: 239\
Incident dementia: 100Incident dementiaProtectiveHigh cognitive activityThe 90+ Study \[[@CR16]\]93 (90--103)No incident dementia: 319\
Incident dementia: 268Incident dementiaEquivocalVascular comorbidityLow total/LDL or high HDL cholesterol levelLeiden 85-plus Study \[[@CR20]\]85 (85)No dementia: 488\
Dementia: 73Cognition\
DementiaEquivocalNewcastle 85+ Study \[[@CR19]\]85 (85)No dementia: 767\
Dementia: 78Cognition\
Cognitive declineEquivocalNonaSantfeliu study \[[@CR21]\]94.3 (±2.6)62, dementia status unknownCognitionNo effectOctabaix study \[[@CR22]\]85 (85)321, dementia status unknownCognitionNo effectPLAD \[[@CR15]\]93.6 (90--108)No cognitive impairment: 300\
Cognitive impairment: 409CognitionNo effectVantaa 85+ Study \[[@CR17]\]88.4 (85.0--104.0)No incident dementia: 239\
Incident dementia: 100Incident dementiaNo effectAbsence of hypertensionLeiden 85-plus Study \[[@CR23]\]85 (85)572, dementia status unknownCognition\
Cognitive declineRiskNewcastle 85+ Study \[[@CR19]\]85 (85)No dementia: 767\
Dementia: 78Cognition\
Cognitive declineEquivocalPLAD \[[@CR27]\]93.6 (90--108)No cognitive impairment: 317\
Cognitive impairment: 465CognitionNo effectUmeå 85+ study \[[@CR26]\]85, 90 and ≥ 95No dementia: 342\
Dementia: 233Cognition\
DementiaProtectiveUmeå 85+ study \[[@CR25]\]88.8 (±4.1)No incident dementia: 136\
Incident dementia: 69Incident dementiaNo effectThe 90+ Study \[[@CR24]\]93.2 (90--103)No incident dementia: 335\
Incident dementia: 224Incident dementiaRiskVantaa 85+ Study \[[@CR17]\]88.4 (85.0--104.0)No incident dementia: 239\
Incident dementia: 100Incident dementiaEquivocalAbsence of DMLeiden 85-plus Study \[[@CR30]\]85 (85)596, dementia status unknownCognition\
Cognitive declineEquivocalOctabaix study \[[@CR31]\]85 (85)167, dementia status unknownCognition\
Cognitive declineNo effectVantaa 85+ Study \[[@CR11]\]≥85No incident dementia: 249\
Incident dementia: 106Incident dementiaProtectiveAbsence of strokeH85 Gothenburg study \[[@CR18]\]85.7 (±0.05)No dementia: 794\
Dementia: 271DementiaProtectiveVantaa 85+ Study \[[@CR32]\]88.4 (±2.9)No dementia: 339\
Dementia: 214\
Incident dementia: 100Dementia\
Incident dementiaProtectiveAbsence of AFVantaa 85+ Study \[[@CR32]\]88.4 (±2.9)No dementia: 339\
Dementia: 214\
Incident dementia: 100Dementia\
Incident dementiaNo effectMood and sleepNo depressionLeiden 85-plus Study \[[@CR34]\]85 (85)500, dementia status unknownCognitionProtectiveUmeå 85+ study \[[@CR14]\]85, 90 and 95--103No dementia: 173\
Dementia: 69DementiaProtectiveHigh sleep qualityPLAD \[[@CR35]\]93.5 (±3.4)No dementia: 251\
Dementia: 409Dementia\
CognitionProtectiveSensory systemAbsence of visual impairmentLeiden 85-plus Study \[[@CR37]\]85 (85)459, dementia status unknownCognitionProtectiveNewcastle 85+ Study \[[@CR38]\]85 (85)No dementia: 771\
Dementia: 68CognitionProtectiveAbsence of glaucoma or cataractNewcastle 85+ Study \[[@CR105]\]85 (85)No dementia: 771\
Dementia: 68CognitionEquivocalAbsence of hearing impairmentLeiden 85-plus Study \[[@CR37]\]85 (85)459, dementia status unknownCognitionEquivocalPhysical performance and capacityGood physical performanceLeiden 85-plus Study \[[@CR40]\]85 (85)555, dementia status unknownCognitionProtectiveThe 90+ Study \[[@CR41]\]93.3 (±2.6)No incident dementia: 366\
Incident dementia: 212Incident dementiaProtectiveHigh physical activityThe 90+ Study \[[@CR16]\]93 (90--103)No incident dementia: 319\
Incident dementia: 268Incident dementiaNo effectGeneticsAbsence of APOEε4 and/or presence of APOEε2Danish 1905 birth cohort \[[@CR42]\]93.1 (±0.3)1551, dementia status unknownCognition\
Cognitive declineNo effectLeiden 85-plus Study \[[@CR43]\]89.0 (87.4--91.2)^b^No dementia: 242\
Dementia: 78DementiaProtectiveThe 90+ Study \[[@CR44]\]93.7 (90--105)No dementia: 566\
Dementia: 236\
Incident dementia: 188Dementia\
Incident dementiaEquivocalVantaa 85+ Study \[[@CR45]\]≥85313 without dementia\
197 with dementiaDementiaProtectiveVantaa 85+ Study \[[@CR46]\]≥85No incident dementia: 187\
Incident dementia: 58Incident dementia\
Cognitive declineNo effectMnSOD, GLRX, GSTP1, MT1A, NDUFV1, PRDX3, UQCRFS1, PICALMDanish 1905 birth cohort \[[@CR106]--[@CR108]\]92-93^c^1089--1650, dementia status unknownCognitionProtectiveACOX1Danish 1905 birth cohort \[[@CR106]\]93.2 (92.7--93.8)1089, dementia status unknownCognitionRiskCytokine genes, CLUDanish 1905 birth cohort \[[@CR108]--[@CR110]\]92-93^c^1380--1651, dementia status unknownCognition\
Cognitive declineEquivocalMTHFR, MTRDanish 1905 birth cohort \[[@CR111]\]93.1 (±0.3)1651, dementia status unknownCognition\
Cognitive declineNo effectKLOTHOPLAD \[[@CR112]\]93.5 (90--108)No cognitive impairment: 236\
Cognitive impairment: 470CognitionProtectivePPAR-γ2PLAD \[[@CR113]\]93.7 (90--108)No cognitive impairment: 257\
Cognitive impairment: 475CognitionNo effectLRP, LPL, ACEVantaa 85+ Study \[[@CR114]\]≥85No dementia: 203\
Dementia (AD): 113DementiaNo effectHallmarks of ageingLow level of inflammation markersLeiden 85-plus Study \[[@CR49]\]85 (85)No dementia: 491Cognition\
Cognitive declineEquivocalThe 90+ Study \[[@CR50]\]94.3 (90--105)No dementia: 232\
Dementia: 73DementiaEquivocalThe 90+ Study \[[@CR51]\]93.9 (90--102)No incident dementia: 145\
Incident dementia: 82Incident dementiaNo effectLow level of senescence markersLeiden 85-plus Study \[[@CR52]\]89.8 (85--101)No dementia: 452\
Dementia: 146\
Incident dementia: unknownCognition\
Dementia\
Incident dementiaNo effectMarkers of neurodegenerationNormal levels of Aβ and tau in CSFH85 Gothenburg study \[[@CR56]\]85 (85)No incident dementia: 28\
Incident dementia: 7Incident dementiaProtectiveNegative amyloid PET-scanThe 90+ Study \[[@CR57]\]94.2 (90--99)^d^No incident dementia: 10\
Incident dementia: 3Cognitive declineProtectiveLess brain atrophyH85 Gothenburg study \[[@CR58]\]85 (85)No dementia: 30\
Dementia: 23DementiaEquivocalLess WMHH85 Gothenburg study \[[@CR59]\]85 (85)No dementia: 133\
Dementia: 103DementiaProtectiveHigh white matter integrityThe 90+ Study \[[@CR60]\]94.6 (90--103)Normal: 64\
CIND: 30CINDNo effect*Aβ* Amyloid β, *AD* Alzheimer's disease, *APOE* Apolipoprotein E, *CIND* Cognitive Impairment, No Dementia, *CSF* cerebrospinal fluid, *DM* diabetes mellitus, *HDL* high-density lipoproteins, *LDL* low-density lipoproteins, *MCI* Mild Cognitive Impairment, *MMSE* Mini-Mental State Examination, *N* Number, *PET* positron emission tomography, *PLAD* Project of Longevity and Aging in Dujangyan, *WMH* white matter hyperintensities^a^Mean age (range, if available, or ± if standard deviation) in years at baseline, unless stated otherwise; ^b^Median age (interquartile range, IQR) in years; ^c^Minimal and maximum mean age in years of the studies referred to; ^d^Median age (range) in years

Data about physical performance and activity have been collected in the Leiden 85-plus study and ***The 90+ Study***. Good physical performance, measured with handgrip strength, 4 m walk or standing balance tests, was associated with better cognitive functioning and lower dementia incidence in the oldest-old but high physical activity did not seem to influence dementia incidence \[[@CR16], [@CR40], [@CR41]\].

With regard to genetics, the Apolipoprotein E (APOE) genotype, a major risk factor for AD in younger subjects, has been extensively studied in the oldest-old, with mixed results regarding the relation to cognition and dementia \[[@CR42]--[@CR46]\]. The Danish 1905 birth cohort, PLAD and Vantaa 85+ Study also studied a number of other genotypes in the oldest-old and found some additional protective and risk genotypes which are described in Table [2](#Tab2){ref-type="table"}.

### Hallmarks of aging and cognition in the oldest-old {#Sec5}

Hallmarks of aging \[[@CR47]\], such as inflammation and cellular senescence \[[@CR48]\], have been scarcely studied in relation to cognition in the oldest-old. The Leiden 85-plus Study and ***The 90+ Study*** related inflammation markers to cognition and dementia but showed mixed results \[[@CR49]--[@CR51]\]. In addition, telomere length measured in white blood cells were not associated with cognition, dementia prevalence or incident dementia \[[@CR52]\].

### Markers of neurodegeneration and cognition in the oldest-old {#Sec6}

Limited information is available about the relation of markers of neurodegeneration, such as amyloid β and tau measured in cerebrospinal fluid (CSF) and/or with a positron emission tomography (PET) scan with cognitive impairment in the oldest-old. Postmortem studies have shown that the prevalence of amyloid aggregation increases with age in cognitively healthy subjects but decreases in the oldest-old subjects with dementia \[[@CR1]\]. A similar trend can be seen with regard to amyloid β measured in CSF or on an amyloid PET scan \[[@CR53], [@CR54]\]. In subjects without dementia, greater amyloid load has been associated with poorer cognitive functioning and a higher rate of incident dementia, although the number of oldest-old subjects in these studies was limited \[[@CR55]--[@CR57]\]. There are a few studies that have related brain MRI measurements in the oldest-old to cognitive functioning. Less atrophy and fewer white matter hyperintensities were seen in subjects without dementia compared to subjects with dementia \[[@CR58], [@CR59]\] but white matter integrity was not related to cognition \[[@CR60]\]. In younger subjects, neurophysiological measures on magnetoencephalography (MEG) have been related to dementia \[[@CR61]\] but it is unknown whether this relationship persists in the oldest-old.

Aims and objectives of the EMIF-AD 90+ study {#Sec7}
--------------------------------------------

The EMIF-AD 90+ Study was set-up to investigate the protective factors for cognitive impairment in the oldest-old. The study was part of the Innovative Medicine Initiative (IMI) European Medical Information Framework for AD (EMIF-AD) project (<http://www.emif.eu/about/emif-ad>) on diagnostic markers, prognostic markers, and protective factors for AD. The EMIF-AD 90+ study focuses on the extreme phenotype of the cognitively normal oldest-old. The primary objectives of the EMIF-AD 90+ study are:i)To identify factors associated with resilience to cognitive impairment in the oldest-old.ii)To test the relationship between hallmarks of aging and cognitive impairment in the oldest-old.iii)To test the relationship between markers of neurodegeneration and cognitive impairment in the oldest-old.

This paper describes the design and protocol of the study.

Methods {#Sec8}
=======

Study subjects {#Sec9}
--------------

We aimed to include 80 cognitively normal subjects and 40 subjects with cognitive impairment, both aged 90 years and older. Inclusion criteria for cognitively normal subjects were a global Clinical Dementia Rating (CDR) score of 0 \[[@CR62]\] and a score ≥ 26 points on the Mini-Mental State Examination (MMSE) \[[@CR63]\]. Inclusion criteria for subjects with cognitive impairment were a diagnosis of amnestic MCI (aMCI) \[[@CR64]\] or a diagnosis of probable or possible AD \[[@CR65]\] by a neurologist, geriatrician, or general practitioner, a global CDR score ≥ 0.5 point (s) and a MMSE score of 20--28 points (inclusive). Exclusion criteria were the physical inability to undergo the procedures, visual or hearing impairment which made neuropsychological testing impossible, severe depression (Geriatric Depression Scale (GDS) score ≥ 11 points \[[@CR66]\]) and other comorbidities or medication that could impair cognition at the discretion of the investigator (e.g. stroke, epilepsy or use of lithium carbonate). During the inclusion period it turned out to be difficult to identify subjects of 90 years and older with aMCI or probable or possible AD; we therefore broadened the inclusion criteria in this group to subjects older than 85 years.

Subjects were recruited at two sites: the Amsterdam UMC, The Netherlands and The University of Manchester, United Kingdom. Cognitively normal subjects were recruited from general practitioners or via advertisements (Amsterdam) or from the Manchester and Newcastle Ageing Study (MNAS, Manchester). Subjects with cognitive impairment were only recruited in the Netherlands. They were recruited from the Alzheimer Center Amsterdam and the Center Of Geriatric medicine Amsterdam (COGA) at the Amsterdam UMC, geriatric departments of other hospitals in the surroundings of Amsterdam, other healthcare facilities (such as a care home), general practitioners or via advertisement. The sample collection started on the 1st of June 2016 and ended on the 30th of June 2018. Currently we are working on the first data analyses.

The Medical Ethics Review Committee of the Amsterdam UMC approved the study in Amsterdam and the National Research Ethics Service Committee North West - Greater Manchester South performed approval of the study in Manchester. The study was carried out in accordance with the ethical conduct and juridical laws of the Declaration of Helsinki 64th WMA General Assembly, Fortaleza, Brazil, October 2013, ([www.wma.net](http://www.wma.net)), and in accordance with the Medical Research Involving Human Subjects Act (WMO). All subjects gave written informed consent.

Study design {#Sec10}
------------

The EMIF-AD 90+ Study is a case-control study in which we search for protective factors for cognitive impairment. Therefore, the cognitively normal subjects are described as cases and the subjects with cognitive impairment as controls.

Study procedures {#Sec11}
----------------

The study consisted of two home visits and one or two visits at the hospital/clinical research facility (CRF). During the first home visit, in- and exclusion criteria (MMSE, CDR, impression of physical ability to undergo the procedures, hearing and visual abilities) were verified, in addition to collection of first study data (Table [3](#Tab3){ref-type="table"}, paragraphs 2.3.1, 2.3.2 and 2.3.4). The MMSE is a short cognitive screening test with a maximum score of 30 points \[[@CR63]\]. The CDR is a scale for the severity of symptoms of dementia, which was assessed by interviews with the subject and, if available, study partner (somebody that is in regular contact with the subject) in combination with judgement by the researchers \[[@CR62]\]. The second home visit consisted of a neuropsychological assessment performed by a neuropsychologist (paragraph 2.3.3). During the hospital/CRF visits several procedures were performed, which are listed in Table [3](#Tab3){ref-type="table"} and described in paragraphs 2.3.4. -- 2.3.10. These procedures provided information on i) potential protective factors (classified in six different domains), ii) hallmarks of aging, and iii) markers of neurodegeneration (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). For each domain, hallmark of aging or markers of neurodegeneration, we will test one or more parameters (Table [3](#Tab3){ref-type="table"}). In most cases, all procedures were performed within three months from start of the inclusion. Any differences in study procedures between Amsterdam and Manchester are explicitly stated in this paper.Table 3The domains of interest in the EMIF-AD 90+ StudyDomainParameterProcedure (measurement)Schedule AmsterdamSchedule ManchesterCognitive reserveLevel of educationInterviewHomeHomeCognitive activityCognitive abilities questionnaireHomeHomeVascular comorbidityCholesterol level, hypertension, DM, stroke, AFBlood collectionHospitalWMICMedical history and medication useHomeHomeBlood pressureHospitalCRFDiagnostick/heart rateHomeCRFUltrasound carotid arteryHospitalCRFMood and sleepDepressive symptomsGeriatric Depression ScaleHomeHomeSleep disorderBerlin Questionnaire and MSQHomeHomeAccelerometer (sleep quality)HomeN/ASensory systemVisual acuityETDRS chartHospitalN/ARetinal thicknessOCTHospitalN/AAuditory functionDigits-in-noise testHomeN/AOlfactory functionSniffin sticksHospitalN/APhysical performance and capacityPhysical performanceGrip strengthHomeCRFShort Physical Performance Battery or 4-min walking testHospitalCRFBIA (muscle mass)HospitalN/APhysical activityAccelerometerHomeN/AGeneticsAPOEε4 and APOEε2Blood collectionHospitalWMICHallmarks of ageingLevel of inflammation markersBlood collection (i.a. PBMCs)HospitalWMICLevel of senescence markersSkin biopsy (senescence markers p16, p53 and telomere associated foci)HospitalN/ANutritional statusBIAHospitalN/ABlood collectionHospitalCRFBMIHospitalCRFMNAHomeN/AMarkers of neurodegenerationAβ1--42 and tau in CSF and bloodCSF collection\
Blood collectionHospitalN/AAmyloid PET scanAmyloid PET scanHospitalWMICBrain atrophyBrain MRI scan or brain CT scanHospitalCRFWMHBrain MRI scan or brain CT scanHospitalCRFWhite matter integrityBrain MRI scanHospitalN/ABrain connectivityBrain MRI scanHospitalCRFMEGHospitalN/A*Aβ* Amyloid β*, AD* Alzheimer's disease, *AF* atrial fibrillation, *APOE* Apolipoprotein E, *BIA* Bioelectrical impedance analysis, *BMI* Body Mass Index, *CRF* Clinical Research Facility, *CT* Computerized Tomography, *CSF* cerebrospinal fluid, *DM* diabetes mellitus, *ETDRS* Early Treatment Diabetic Retinopathy Study, *MEG* magnetoencephalography, *MNA* Mini Nutritional Assessment, *MRI* Magnetic Resonance Imaging, *MSQ* Mayo Sleep Questionnaire, *N/A* not applicable, *OCT* Optical Coherence Tomography, *PBMCs* Peripheral Blood Mononuclear Cells, *PET* positron emission tomography, *PLAD* Project of Longevity and Aging in Dujangyan, *WMH* white matter hyperintensities, *WMIC* Wolfson Molecular Imaging CentreFig. 1Overview of the domains of interest in the EMIF-AD 90+ Study. *Aβ* Amyloid β*, CSF* cerebrospinal fluid, *PET* positron emission tomography

### Interview {#Sec12}

Data about the medical and family history, medication use, education and intoxications (alcohol use and smoking) were collected through a structured interview, in combination with information provided by the study partner (if available), general practitioner and/or medical specialist.

### Questionnaires {#Sec13}

In Amsterdam, subjects were asked to complete six questionnaires. Activities of daily living (ADL) were evaluated by use of the Katz ADL \[[@CR67]\]. Functional health and wellbeing were evaluated by the Short form-12 Health-related Quality of Life (SF-12 HRQoL) questionnaire \[[@CR68]\] and by the Cognitive Complaints Index (CCI) \[[@CR69]\]. Nutrition was evaluated by the Mini Nutritional Assessment (MNA-long version) \[[@CR70]\]. Sleep disorders were evaluated by use of the Berlin Questionnaire which identifies the risk of sleep disordered breathing \[[@CR71]\]. Cognitive activity during life, such as reading books and playing games, was assessed with the cognitive abilities questionnaire \[[@CR72]\]. Subjects with cognitive impairment filled in the questionnaires together with a study partner. The GDS was filled in together with the researcher \[[@CR66]\].

In Amsterdam, the study partner was asked to complete five questionnaires: the AD8 (an 8-question test for the study partner to assess mild dementia) \[[@CR73]\], the Amsterdam instrumental Activities of Daily Living (iADL) scale (a study partner based tool aimed at detecting iADL problems in early dementia) \[[@CR74], [@CR75]\], the Neuropsychiatric Inventory Questionnaire (NPI-Q, to assess the severity of behavioral symptoms in the subject and the distress these symptoms cause in the study partner) \[[@CR76]\], the Mayo Sleep Questionnaire (MSQ, to screen for the presence of Rapid Eye Movement (REM) sleep disorders) \[[@CR77]\], and finally the CCI \[[@CR69]\].

In Manchester, subjects were asked to complete the SF-12 HRQoL questionnaire \[[@CR68]\], the Physical Activity Scale for the Elderly (PASE) \[[@CR78]\], the CCI \[[@CR69]\] and the cognitive abilities questionnaire \[[@CR72]\]. The study partner was asked to complete the AD8 \[[@CR73]\], the Functional Activities Questionnaire (FAQ) \[[@CR79]\] and the CCI \[[@CR69]\].

### Neuropsychological assessment {#Sec14}

The neuropsychological assessment took approximately one and a half hours during which several cognitive domains were tested. Table [4](#Tab4){ref-type="table"} gives an overview of the different cognitive tests that were administered, which domain they examine and at which site they were performed.Table 4Cognitive tests in the EMIF-AD 90+ StudyCognitive testCognitive domainSiteCERAD 10 words test \[[@CR115]\]\
 Immediate recall\
 Delayed recall after 10 minMemoryB^a^Logical Memory test \[[@CR116]\]\
 Immediate recall\
 Delayed recall after 20--30 minMemoryARey Auditory Verbal Learning Test \[[@CR117]\]\
 Immediate recall\
 Delayed recall after 20 minMemoryMRey Complex Figure Test \[[@CR118]\]\
 Copy\
 Delayed copy after 3 minMemory\
Visuoconstructive skillsBWAIS-III Digit span forward and backward \[[@CR119], [@CR120]\]Executive functioningBAnimal (2 min) and Letter fluency (1 min per letter^b^) \[[@CR121]\]Executive functioningBClock Drawing Test^c^ \[[@CR122]\]Executive functioning\
Visuospatial functioningAGraded Naming Test \[[@CR123]\]Object-naming abilityBTrail Making Test A and B \[[@CR124]\]Information processing speed\
Visual attention\
Task switchingBWAIS-R Digit Symbol Substitution Test \[[@CR125]\]Perceptual-motor speed\
Incidental learningBComputerised Cambridge Neuropsychological Test Automated battery \[[@CR126]\]Paired associate learning\
Spatial-working memory\
Reaction timeBNational Adult Reading Test \[[@CR127]\]Pre-morbid IQBVisual Association Test \[[@CR128]\]Visuospatial association learningAAddenbrooke's Cognitive Examination Revised battery \[[@CR129]\]Attention/orientation\
Memory\
Verbal fluency\
Language\
Visuospatial abilitiesM*A* administered only in Amsterdam, *B* administered in Amsterdam and Manchester, *CERAD* Consortium to Establish a Registry for Alzheimer's Disease, *M* administered only in Manchester, *min* minute (s), *WAIS (−R)* Wechsler Adult Intelligence Scale (-Revised)^a^In Manchester only in the cognitively normal subjects. ^b^In Amsterdam using the letters D, A and T and in Manchester the letters F, A, and S. ^c^The subject will be asked to draw a clock showing the time "ten after eleven". In total 14 points can be scored based on the presence and sequencing of the numbers and the positioning of the two hands

### Physical examination {#Sec15}

In Amsterdam, data on waist and hip circumference (cm), and hand grip strength (kg), as well as a standard neurologic screening examination were recorded during the first home visit. Hand grip strength was measured to estimate muscle strength and was performed with a hand dynamometer (Jamar hand dynamometer; Sammons Preston, Inc., Bolingbrook, IL., USA) \[[@CR80]\]. In addition, a 'Diagnostick' was used to determine whether the subject had atrial fibrillation by measuring one derivative of an electrocardiogram \[[@CR81]\]. At the end of the first home visit, the subject was asked to wear an accelerometer (DynaPort MoveMonitor, McRoberts B.V., The Hague, The Netherlands) for seven days to measure physical activity and sleep quality.

During the hospital visit in Amsterdam, continuous blood pressure measurements were performed non-invasively using a digital photoplethysmogram on the right middle finger (Nexfin®, BMEYE, Amsterdam, The Netherlands), resulting in beat-to-beat BP data. The Short Physical Performance Battery (SPPB) included balance tests, a 4 m walk to measure walking speed and the chair stand test \[[@CR82]\]. Body composition, including the Body Mass Index (BMI), was measured using a Bioelectrical Impedance Analysis (BIA; InBody 770; Biospace Co., Ltd., Seoul, Korea).

In Manchester, waist and hip circumference (cm), hand grip strength (kg), BMI, resting blood pressure, heart rate, ankle/brachial pressure index \[[@CR83]\] and a 4 min walking test were recorded at the clinical research facility.

### Sensory system {#Sec16}

Measurements of the sensory system were only performed in Amsterdam. With regard to visual functioning, best corrected visual acuity was tested with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Intra-Ocular Pressure (IOP) and refraction data of all subjects were obtained, and all subjects underwent slit lamp examination and indirect fundoscopy. Pupils were dilated using tropicamide 0.5% and phenylephrine 5%. Peripapillary Retinal Nerve Fiber Layer (pRNFL) thickness and macular (layer) thickness were measured with Spectral Domain Optical Coherence Tomography (SD-OCT, Heidelberg Spectralis) using Heidelberg's build-in software \[[@CR84]\]. With enhanced depth imaging, the choroid was imaged and its thickness was (manually) measured. With fundus photography (Topcon TRC 50DX type IA), we acquired digital fundus images (50°). From these, seven Retinal Vascular Parameters (RVPs) were obtained using Singapore I Vessel Assessment (SIVA, version 3.0) \[[@CR85]\].

For the auditory function, we used the digits-in-noise (DIN) test \[[@CR86]\]. The DIN test is a speech-in-noise test using digit triplets as speech material. The digit triplets are presented against a constant level of stationary background noise. The test uses an adaptive procedure to determine the signal-to-noise ratio at which a listener understands 50% of the digit triplets correctly (i.e. the speech reception threshold (SRT) in noise). Olfactory function was measured using "Sniffin' Sticks" (Burghart, Wedel, Germany). The test consists of pen-like odor dispensing devices with odors that are considered to be familiar. The smell test in the present study contained the odor identification part of the test \[[@CR87]\].

### Blood collection and skin biopsy {#Sec17}

In both centers, blood samples were collected according to the biobanking pre-analytical Standard Operating Procedures (SOPs) of the Biomarkers for Alzheimer's disease and Parkinson's disease (BIOMARKAPD) project \[[@CR88]\]. Blood samples were collected for DNA and RNA analysis, inflammation markers, proteomics, neurodegenerative markers (amyloid β, tau, neurofilament light), routine blood analysis (i.e. lipids and glucose), vitamin status (B12 and folic acid) and, in Amsterdam only, for Peripheral Blood Mononuclear Cells (PBMCs). Planned DNA analysis includes Single Nucleotide Polymorphisms (SNP) analysis of known genetic risk factors for AD or amyloid pathology \[[@CR89]--[@CR92]\]. DNA and RNA isolation will be performed by EMIF-AD partners. Remaining samples will be stored for future biomarker identification and validation studies.

In Amsterdam, four millimeter skin biopsies were taken from the inner upper medial arm and will be stained for senescence markers p16, p53 and telomere associated foci.

### Cerebrospinal fluid collection {#Sec18}

In Amsterdam, up to 20 mL CSF was obtained by lumbar puncture in Sarstedt polypropylene syringes using a Spinocan 25 Gauge needle in one of the intervertebral spaces between L3 and S1. A half mL CSF was immediately processed for leukocyte count, erythrocyte count, glucose, and total protein. The remaining CSF was mixed and centrifuged at 1300--2000 × *g* at 4 °C for ten minutes. Supernatants were stored in aliquots of 0.25--0.5 mL and frozen within two hours at − 80 °C and stored for future biomarker discovery studies. The processing and storing of CSF was performed according to the BIOMARKAPD SOP \[[@CR88]\]. Amyloid β 1--42, total tau and phosphorylated tau 181 will be analyzed in a single batch. Remaining samples will be stored for future biomarker identification and validation studies.

### Ultrasound carotid artery {#Sec19}

At both sites, a duplex ultrasound scan of the carotid artery was performed. In Amsterdam, the right carotid artery was scanned to assess intima media thickness and distension using ArtLab software \[[@CR93], [@CR94]\]. In Manchester, left and right carotid arteries were scanned to determine velocity, vessel thickness, stenosis and plaques, rated according to the North American Symptomatic Carotid Endarterectomy Trial guidelines \[[@CR95]\].

### Brain MRI scan {#Sec20}

Subjects underwent locally optimized brain MRI protocols including 3D-T1, fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), diffusion tensor imaging (DTI) and resting state functional MRI (rs-fMRI). MRI scans were performed on Philips 3 T Achieva scanners. Additionally, in Manchester regional cerebral blood flow was measured by arterial spin labelling \[[@CR96]\], but no DTI scan was acquired in Manchester. In Amsterdam, if a subject could not undergo the MRI scan, we considered a CT scan (Philips Ingenuity TF or Gemini TF camera). Scans will be analyzed locally and centrally by EMIF-AD partners using the Neugrid infrastructure if applicable (see Additional file [1](#MOESM1){ref-type="media"}).

### Amyloid PET scan {#Sec21}

\[^18^F\] Flutemetamol, a specific fibrillary amyloid β radiotracer, was used for the amyloid PET scans. In Amsterdam, \[^18^F\] flutemetamol was produced by General Electric (GE) Healthcare at the Cyclotron Research Center of the University of Liège (Liège, Belgium) and PET scans were performed using a Philips Ingenuity TF PET-MRI scanner (Philips Medical Systems, Cleveland, Ohio, USA) or, in case of a PET-CT scan, the Philips Ingenuity TF (Philips Medical Systems, Best, the Netherlands) or Gemini TF scanner (Philips Medical Systems, Best, the Netherlands). In Manchester, \[^18^F\] flutemetamol was produced at the Wolfson Molecular Imaging Centre (WMIC)'s Good Manufacturing Practice radiochemistry facility using GE Healthcare's FASTlab and cassettes and PET scans were performed using a High Resolution Research Tomograph (HRRT; Siemens/CTI, Knoxville, TN). In both centers, the emission scan was performed in two parts. First a 30 min dynamic emission scan was started simultaneously with a bolus intravenous injection of 185 MBq \[^18^F\] flutemetamol. The second part of the scan was performed from 90 to 110 min post injection. In Amsterdam, immediately before each part of the PET scan a T1-weighted gradient echo pulse MRI or low dose CT scan was obtained. This MRI or CT scan was used for attenuation correction of the PET scan. In Manchester, two seven minute transmission scans, one before the first emission scan and the other after the second emission scan, using a ^137^Cs point source were acquired for subsequent attenuation and scatter correction.

All \[^18^F\] flutemetamol scans were read visually as positive or negative. Additionally, we determined time activity curves for each region of interest with cerebellum grey matter as input function \[[@CR97]\]. The dynamic data were analyzed on a voxel-by-voxel level using the Simplified Reference Tissue Model 2 (SRTM2) \[[@CR98], [@CR99]\]. Finally, we investigated tracer uptake by using a simplified method: the standardized uptake value ratio (SUVr, target to grey matter cerebellum SUV over 90--110 min pi) \[[@CR100]\]. Variability in acquisition of amyloid PET scans were reduced by harmonizing acquisition protocols and will be reduced by adding it to the analyses as a covariate.

### Neurophysiology {#Sec22}

In Amsterdam, MEG was performed using a 306 channel whole-head system (Elekta Neuromag Oy, Helsinki, Finland). Eyes-closed and eyes-open resting-state MEG data were recorded with subjects in supine position inside a magnetically shielded room. We will use transformed time series \[[@CR101]\] to extract spectral properties (relative band power and peak frequency) \[[@CR102]\], and estimates of functional connectivity between brain regions, and metrics that characterize the topology of the functional brain networks \[[@CR103], [@CR104]\]. These analyses will be applied using Elekta's beamformer software, and both in-house developed Matlab tools and BrainWave software (<http://home.kpn.nl/stam7883/brainwave.html>).

Planned statistical analyses {#Sec23}
----------------------------

For each parameter listed in Table [3](#Tab3){ref-type="table"}, we will test with logistic regression models whether it is associated with resilience to cognitive impairment. In addition, linear regression models will be used to associate the same parameters with cognitive functioning in the total sample. Potential additional analyses include the identification of protective factors for abnormal AD biomarkers in the subsample of cognitively normal subjects and the identification of protective factors for cognitive impairment in subjects with a high risk, for example APOE ε4 carriers.

Discussion {#Sec24}
==========

We described the design of the EMIF-AD 90+ Study that aims to unravel the factors associated with resilience to cognitive impairment in the oldest-old. An important additional value of the EMIF-AD 90+ Study compared to the previous studies is the extensive phenotyping of subjects, which includes data about cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity and genetic risk factors. Furthermore, the EMIF-AD 90+ Study is one of the first studies that collects a broad range of markers of neurodegeneration in the oldest-old, including an amyloid PET scan, amyloid β and tau measured in CSF and blood and neurophysiological measures.

The EMIF-AD 90+ is the first study worldwide that combines data regarding the hallmarks of aging with markers of neurodegeneration. The process of aging and the incidence of aMCI and possible or probable AD are very much interrelated. Our study allows to test hypotheses such as that common risk factors and pathways drive both the aging process and development of cognitive impairment or AD. Another strength of the EMIF-AD 90+ study is that we use objective measures wherever possible, instead of using questionnaires. For example, physical activity and sleep quality were measured with an accelerometer in Amsterdam.

To conclude, the results of the EMIF-AD 90+ Study will provide an important contribution to the existing literature in many different ways. It will extend our knowledge on protective factors for cognitive impairment in the oldest-old and will determine how hallmarks of aging and markers of neurodegeneration relate to cognitive impairment in this specific age group.

Additional file
===============

 {#Sec25}

Additional file 1:**Table S1.** Brain MRI scan analyses in the EMIF-AD 90+ Study. (DOCX 26 kb)

ACE-R

:   Addenbrooke's Cognitive Examination Revised

AD

:   Alzheimer's disease

ADL

:   Activities of daily living

Amsterdam UMC

:   Amsterdam University Medical Centers

APOE

:   Apolipoprotein E

Aβ

:   Amyloid β

BIA

:   Bioelectrical Impedance Analysis

BIOMARKAPD

:   Biomarkers for Alzheimer's disease and Parkinson's disease

BMI

:   Body Mass Index

CANTAB

:   Cambridge Neuropsychological Test Automated battery

CCI

:   Cognitive Complaints Index

CDR

:   Clinical Dementia Rating

CERAD

:   Consortium to Establish a Registry for Alzheimer's Disease

COGA

:   Center Of Geriatric medicine Amsterdam

CSF

:   cerebrospinal fluid

DIN test

:   digits-in-noise test

DSST

:   Digit Symbol Substitution Test

DTI

:   diffusion tensor imaging

EMIF-AD

:   European Medical Information Framework for AD

ETDRS

:   Early Treatment Diabetic Retinopathy Study

FLAIR

:   fluid attenuated inversion recovery

GDS

:   Geriatric Depression Scale

GE

:   General Electric

GNT

:   Graded Naming Test

HRRT

:   High Resolution Research Tomograph

iADL

:   instrumental Activities of Daily Living

IMI

:   Innovative Medicine Initiative

IOP

:   Intra-Ocular Pressure

MEG

:   magnetoencephalography

MMSE

:   Mini-Mental State Examination

MNA

:   Mini Nutritional Assessment

MNAS

:   Manchester and Newcastle Aging Study

MSQ

:   Mayo Sleep Questionnaire

N/A

:   not applicable

NART

:   National Adult Reading Test

NPI-Q

:   Neuropsychiatric Inventory Questionnaire

OCT

:   Optical Coherence Tomography

PASE

:   Physical Activity Scale for the Elderly

PBMCs

:   Peripheral Blood Mononuclear Cells

PET

:   positron emission tomography

PLAD

:   Project of Longevity and Aging in Dujangyan

pRNFL

:   peripapillary Retinal Nerve Fiber Layer

RAVLT

:   Rey Auditory Verbal Learning Test

RCFT

:   Rey Complex Figure Test

REM

:   Rapid Eye Movement

rs-fMRI

:   resting state functional MRI

RVPs

:   Retinal Vascular Parameters

SD-OCT

:   Spectral Domain Optical Coherence Tomography

SF-12 HRQoL

:   Short form 12 Health-related Quality of Life

SIVA

:   Singapore I vessel Assessment

SNP

:   Single Nucleotide Polymorphisms

SOP

:   Standard Operating Procedure

SPPB

:   Short Physical Performance Battery

SRT

:   speech reception threshold

SRTM2

:   Simplified Reference Tissue Model 2

SUVr

:   standardized uptake value ratio

SWI

:   susceptibility weighted imaging

TMT

:   Trail Making Test

VAT

:   Visual Association Test

WAIS

:   Wechsler Adult Intelligence Scale

WMH

:   white matter hyperintensities
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